Everyday Health on MSN

How weight loss pills have changed — and what that means for safety

Weight loss pills have been around for decades, but many were deemed unsafe by the FDA. Learn more about today’s ...
Healio

Fenfluramine linked to significantly improved seizure outcomes vs. placebo at 14 weeks

Please provide your email address to receive an email when new articles are posted on . The treatment group recorded a greater median reduction in countable motor seizure frequency vs. placebo.
Pharmabiz

UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces CMSF in CDKL5 deficiency disorder

UCB, a global biopharmaceutical company, presented positive efficacy and safety results from the GEMZ phase 3 study investigating adjunctive fenfluramine in children and adults with CDKL5 Deficiency ...
The Korea Herald

UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder

"UCB is proud to share these important results with the medical community at AES, especially given the significant unmet need in CDD. Families affected by this ultra-rare condition face immense daily ...
Finanznachrichten

UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder

Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in countable motor seizure frequency (CMSF) compared with placebo 1 ...
Europa Press

UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor

BRUSSELS, Dec. 8, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today presented positive efficacy and safety results from the GEMZ phase 3 study investigating adjunctive fenfluramine ...
AdnKronos

UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder

BRUSSELS, Dec. 8, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today presented positive efficacy and safety results from the GEMZ phase 3 study investigating adjunctive fenfluramine ...